[1] Sánchez-Martínez R, Iriarte A, Mora-Luján JM, Patier JL, López-Wolf D, Ojeda A, Torralba MA, Juyol MC, Gil R, A?ón S, Salazar-Mendiguchía J, Riera-Mestre A; RiHHTa Investigators of the Rare Diseases Working Group from the Spanish Society of Internal Medicine. Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry[J]. Orphanet J Rare Dis, 2020, 15: 138.
[2] Floria M, N?fureanu ED, Iov DE, S?rbu O, Dranga M, Ouatu A, T?nase DM, B?rboi OB, Drug VL, Cobzeanu MD. Hereditary hemorrhagic telangiectasia and arterio-venous malformations: from diagnosis to therapeutic challenges[J]. J Clin Med, 2022, 11: 2634.
[3] Kroon S, Snijder RJ, Faughnan ME, Mager HJ. Systematic screening in hereditary hemorrhagic telangiectasia: a review[J]. Curr Opin Pulm Med, 2018, 24: 260-268.
[4] Thompson KP, Nelson J, Kim H, Pawlikowska L, Marchuk DA, Lawton MT, FaughnanME; Brain Vascular Malformation Consortium HHT Investigator Group. Predictors of mortality in patients with hereditary hemorrhagic telangiectasia[J]. Orphanet J Rare Dis, 2021, 16: 12.
[5] Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)[J]. Am J Med Genet, 2000, 91: 66-67.
[6] Viteri-No?l A, González-García A, Patier JL, Fabregate M, Bara-Ledesma N, López-Rodríguez M, Gómez Del Olmo V, Manzano L. Hereditary hemorrhagic telangiectasia: genetics, pathophysiology, diagnosis, and management[J]. J Clin Med, 2022, 11: 5245.
[7] Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective[J]. Haematologica, 2018, 103: 1433-1443.
[8] Capasso TL, Li B, Volek HJ, Khalid W, Rochon ER, Anbalagan A, Herdman C, Yost HJ, Villanueva FS, Kim K, Roman BL. BMP10-mediated ALK1 signaling is continuously required for vascular development and maintenance[J]. Angiogenesis, 2020, 23: 203-220.
[9] Brinjikji W, Iyer VN, Sorenson T, Lanzino G. Cerebrovascular manifestations of hereditary hemorrhagic telangiectasia[J]. Stroke, 2015, 46: 3329-3337.
[10] Bofarid S, Hosman AE, Mager JJ, Snijder RJ, Post MC. Pulmonary vascular complications in hereditary hemorrhagic telangiectasia and the underlying pathophysiology[J]. Int J Mol Sci, 2021, 22: 3471.
[11] Olsen LB, Kjeldsen AD, Poulsen MK, Kjeldsen J, Fialla AD. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment[J]. Orphanet J Rare Dis, 2020, 15: 334.
[12] Huang HY, Ma HS, Yang JL. A case of hepatic encephalopathy induced by hereditary hemorrhagic telangiectasia[J]. Zhonghua Gan Zang Bing Za Zhi, 2022, 30: 323-325. 黄虹玉, 马洪升, 杨锦林. 遗传性出血性毛细血管扩张症诱发肝性脑病1例[J]. 中华肝脏病杂志, 2022, 30: 323-325.
[13] Vorselaars VMM, Hosman AE, Westermann CJJ, Snijder RJ, Mager JJ, Goumans MJ, Post MC. Pulmonary arterial hypertension and hereditary haemorrhagic telangiectasia[J]. Int J Mol Sci, 2018, 19: 3203.
[14] Hetts SW, Shieh JT, Ohliger MA, Conrad MB. Hereditary hemorrhagic telangiectasia: the convergence of genotype, phenotype, and imaging in modern diagnosis and management of a multisystem disease[J]. Radiology, 2021, 300: 17-30.
[15] Brinjikji W, Iyer VN, Wood CP, Lanzino G. Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis[J]. J Neurosurg, 2017, 127: 302-310.
[16] Vella M, Alexander MD, Mabray MC, Cooke DL, Amans MR, Glastonbury CM, Kim H, Wilson MW, Langston DE, Conrad MB, Hetts SW. Comparison of MRI, MRA, and DSA for detection of cerebral arteriovenous malformations in hereditary hemorrhagic telangiectasia[J]. AJNR Am J Neuroradiol, 2020, 41: 969-975.
[17] Kim H, Nelson J, Krings T, terBrugge KG, McCulloch CE, Lawton MT, Young WL, Faughnan ME; Brain Vascular Malformation Consortium HHT Investigator Group. Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia[J]. Stroke, 2015, 46: 1362-1364.
[18] Al-Samkari H. Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care[J]. Blood, 2021, 137: 888-895.
[19] Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, Vázquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study[J]. Haematologica, 2021, 106: 2161-2169.
[20] Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia[J]. Nat Med, 2010, 16: 420-428.
[21] Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, Suppressa P, Zarrabeitia R, Dupuis-Girod S, Shovlin CL; VASCERN-HHT. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia[J]. Orphanet J Rare Dis, 2019, 14: 28.
[22] Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Future treatments for hereditary hemorrhagic telangiectasia[J]. Orphanet J Rare Dis, 2020, 15: 4.
[23] Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, Deslandres E, Kasthuri RS, Lausman A, Poetker D, Ratjen F, Chesnutt MS, Clancy M, Whitehead KJ, Al-Samkari H, Chakinala M, Conrad M, Cortes D, Crocione C, Darling J, de Gussem E, Derksen C, Dupuis-Girod S, Foy P, Geisthoff U, Gossage JR, Hammill A, Heimdal K, Henderson K, Iyer VN, Kjeldsen AD, Komiyama M, Korenblatt K, McDonald J, McMahon J, McWilliams J, Meek ME, Mei-Zahav M, Olitsky S, Palmer S, Pantalone R, Piccirillo JF, Plahn B, Porteous MEM, Post MC, Radovanovic I, Rochon PJ, Rodriguez-Lopez J, Sabba C, Serra M, Shovlin C, Sprecher D, White AJ, Winship I, Zarrabeitia R. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia[J]. Ann Intern Med, 2020, 173: 989-1001. |